YNT-185 is a non-peptide, selective orexin type 2 receptor (OX2R) agonist/activator with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 improves episodic paralysis symptoms in mouse models.

Physicochemical Properties

Molecular Formula	C33H37N5O5S
Molecular Weight	615.74
Exact Mass	615.251
CAS #	1804978-81-1
Related CAS #	YNT-185 dihydrochloride;1804978-82-2
PubChem CID	122192250
Appearance	Off-white to light yellow solid powder
LogP	4.6
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	12
Heavy Atom Count	44
Complexity	1030
Defined Atom Stereocenter Count	0
SMILES	C1(C2=CC=C(OC)C(S(NC3=CC=CC(NCCNC(=O)C4=CC=CC=C4N(C)C)=C3)(=O)=O)=C2)=CC=CC(C(N(C)C)=O)=C1
InChi Key	BXJSAMKIFDDLGI-UHFFFAOYSA-N
InChi Code	InChI=1S/C33H37N5O5S/c1-37(2)29-15-7-6-14-28(29)32(39)35-19-18-34-26-12-9-13-27(22-26)36-44(41,42)31-21-24(16-17-30(31)43-5)23-10-8-11-25(20-23)33(40)38(3)4/h6-17,20-22,34,36H,18-19H2,1-5H3,(H,35,39)
Chemical Name	2-(dimethylamino)-N-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]benzamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	Mice exposed to YNT-185 (20–40 mg/kg; ip) become more awake[2]. In wild-type mice, but not in OXRDKO mice, YNT-185 (300 nmol; icv) dramatically lengthens wake time for three hours in a dose-dependent manner, concomitant with a reduction in NREM sleep time[2].
Animal Protocol	Animal/Disease Models: Male wild-type C57BL/6J mice[2] Doses: 20, 40 mg/kg Route of Administration: Ip Experimental Results: Wake time was also Dramatically increased.
References	[1]. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J Med Chem. 2015;58(20):7931-7937. [2]. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114(22):5731-5736.

Solubility Data

Solubility (In Vitro)

DMSO: 100 mg/mL (162.41 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (4.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	1.6241 mL	8.1203 mL	16.2406 mL
	5 mM	0.3248 mL	1.6241 mL	3.2481 mL
	10 mM	0.1624 mL	0.8120 mL	1.6241 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.